Search
for
Sort by
Research 271–300 of 1000+
- Cytokine Targeted Therapeutics for Alopecia Areata: Lessons from Atopic Dermatitis and Other Inflammatory Skin Diseases
- Alopecia Areata: A Complex Cytokine Driven Disease
- LB943 Tofacitinib treatment of inflammatory skin conditions in patients with Down Syndrome
- Effectiveness and safety of baricitinib in patients with severe alopecia areata: a 36-week multicenter real-world experience
- JAK inhibition decreases the autoimmune burden in Down syndrome
- Janus Kinase (JAK) Inhibitors in Dermatology: An Update and Critical Review
- Alopecia Areata: JAK Inhibitors—PRP and Exosomes
- Systemic immunotherapies
- 290 Brepocitinib improves cicatricial alopecia and downregulates key T-helper biomarkers
- The Use of Janus Kinase Inhibitors in Alopecia Areata: A Review of the Literature
- Janus Kinase inhibitors in dermatology: a review
- Therapeutic expansion of JAK inhibitors in Chinese dermatological practice: beyond atopic dermatitis to novel autoimmune frontiers
- A Comprehensive Review on Alopecia Areata and its Pathophysiology, Diagnosis, Treatment, and Psychosocial Impact
- A Comprehensive Review on Alopecia Areata and its Pathophysiology, Diagnosis, Treatment, and Psychosocial Impact
- ‘Neurotrophology’ of the hair follicle: neurotrophins act as auto‐ and paracrine growth factors and immunomodulators
- Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition
- Alopecia Areata: a Comprehensive Review of Pathogenesis and Management
- Overlapping features of atopic dermatitis and alopecia areata: from pathogenesis to treatment
- Penatalaksanaan Alopecia Areata (Treatment of Allopecia Areata)
- CS12192 Reverses Alopecia Areata by Selectively Targeting JAK3/JAK1/TBK1.
- Cutaneous Toxicities of Advanced Treatment for Cutaneous Melanoma: A Prospective Study from a Single-Center Institution
- Lichen planopilaris: retrospective study on the characteristics and treatment of 291 patients
- Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream
- Clinical positioning and future prospects of JAK inhibitors in alopecia areata
- TYK2 Inhibition with Deucravacitinib Improves Clinical Outcomes and Resolves Interferon-Driven Inflammation in Lichen Planopilaris
- Case Report: Vitiligo and Alopecia Universalis Following Rituximab Therapy in a Patient with Myasthenia Gravis
- Review of Promising Off-Label Use of Deucravacitinib
- A Single Subcutaneous Dose of BMD-1141 Stimulates Hair Regrowth Comparable to Daily, High-Dose Ruxolitinib in a Mouse Model of Alopecia Areata.
- Psoriatic Alopecia: Clinical Features, Pathogenesis, and Emerging Treatment Strategies
- Involvement of RIPK1 in Alopecia Areata